Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Metastatic Hepatocellular Carcinoma (HCC). According to... Likelihood of Approval and Phase Transition Success ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine program. Back in 2020, the Roche subsidiary inked a worldwide licensing ...

Feel free to distribute or cite this material, but please credit OpenSecrets. For permission to reprint for commercial uses, such as textbooks, contact OpenSecrets: [email protected] ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

USA I October 18, 2024 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from the open-label, single-arm Phase IV ELEVATUM study ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

Are you a print subscriber? Activate your account. By Ad Age Studio 30 - 1 day 13 hours ago By Ad Age Staff - 1 day 15 hours ago By Ad Age and Creativity Staff - 1 day 17 hours ago 1 day 19 hours ago ...

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential ...

Xilio is leveraging its proprietary platform to advance a pipeline of research-stage programs for tumor-activated bispecific ...